EVALUATION OF THE COST-EFFECTIVENESS OF CONCOMITANT ORAL AND TOPICAL MESALAZINE TREATMENT VERSUS ORAL TREATMENT ALONE IN MILD-TO-MODERATE ACTIVE ULCERATIVE COLITIS: A DECISION-ANALYTIC MODEL
Nielsen SK1, Connolly MP1, Bhac A1, Currie CJ2
1Ferring International Center, Saint-Prem, Switzerland, 2Cardiff University, Cardiff, UK

OBJECTIVES: The purpose of the study was to evaluate the cost-effectiveness of concomitant oral plus enema mesalazine therapy versus oral mesalazine alone in mild-to-moderate active ulcerative colitis (UC). METHODS: Outcome data from a randomised controlled, double-blind trial comparing mesalazine 4 g oral plus 1 g enema (Oral + Enema) versus mesalazine 4 g oral plus placebo enema (Oral-Alone) were used. A deterministic decision-analytic model was constructed using trial and published data sources. Two health states were considered in the model: acute bleeding and remission. The base case evaluation assessed costs and outcomes over the trial duration (8 weeks). A second evaluation assessed cost and outcomes up to 26 weeks. Taking into consideration additional treatment with steroids, ciclosporin and surgery to achieve remission. The evaluation perspective was that of the UK National Health Service and cost data were derived from published sources. Health-related quality of life data was extracted from the clinical trial to derive quality adjusted life years (QALYs) for evaluation within the model. Sensitivity analysis was carried out where appropriate.

RESULTS: Baseline case cost-effectiveness ratios were £9,813/QALY for Oral + Enema and £9,708/QALY for Oral-Alone, with an incremental cost per QALY of £14,094. At 8 weeks the incremental cost difference was £44 for Oral + Enema, which was less than the cost of enema therapy over the trial period, suggesting that Oral + Enema results in cost-savings elsewhere in the health system. At 26 weeks Oral + Enema was both cost-saving and more efficacious. The model suggests that adopting a Oral + Enema treatment strategy in this population can save £82 per person.

CONCLUSION: Oral + Enema treatment was more cost-effective at 8 weeks than Oral-Alone based on accepted cost-effectiveness thresholds in the UK of £20,000/QALY. At 26 weeks Oral + Enema therapy was cost-saving and more efficacious compared with Oral-Alone because of improved remission rates, which prevents UC patients from progressing to more expensive interventions.

PHARMACOECONOMIC ANALYSIS OF PROTON PUMP INHIBITORS ON C & D ESOPHAGITIS TREATMENT IN SPAIN
Cordero L1, Jimenez J1, Hernandez R2, Coll E1
1Astrazeneca Farmacéutica Spain S.A, Madrid, Spain, 2Astrazeneca, Madrid, Spain

OBJECTIVES: Determine which new generation proton pump inhibitor (PPI) is most cost-effective in the maintenance phase of patients with C & D esophagitis as well as their expected impact on Spanish NHS budget. METHODS: A pharmacoeconomic deterministic model, NHS perspective, was developed to compare esomeprazole (ESO40 mg/d), lansoprazole (LANSO30 mg/d) and pantoprazole (PANTO40 mg/d) in the maintenance phase of patients with C&D esophagitis. The effectiveness measure considered was symptoms free-days after 12 months of treatment. And the costs included were drugs and health care utilization resources (diagnostic methods, physicians visits and surgery), expressed as 2006€. Moreover a budget impact model was done to know the affordability of most cost-effective drug utilization in a 1000 patients cohort. RESULTS: ESO provide higher remission rates (308 days without symptoms) than the other alternatives: LANSO-231 days; PANTO-270 days. The annual cost by patient are: 794€-ESO, 885€-LANSO, 772€-PANTO. The analysis indicates that ESO being a dominant therapy vs. LANSO; and vs. PANTO presents an incremental cost-effectiveness ratio of 0.59 €/day. The expected cost by patient is 822.32€ (259 symptoms free-days), based on 2006 treatment patterns. Increasing the ESO utilization on 25, 50, 75 & 100%, instead of less effective and costly drugs, could produce potential savings for the Spanish NHS: 1370€, 2850€, 4120€ & 6190€, respectively; which would allow treatment of more patients with the same budget: 2, 3, 5 and 8 additional patients, correspondingly. CONCLUSION: ESO is the most cost-effective and efficient PPI in for treatment of patients for the maintenance of C&D esophagitis treatment in Spain.

COST-EFFECTIVENESS ANALYSIS OF TREATING CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN EARLY BEFORE DISEASE PROGRESSES TO MORE ADVANCED STAGE
Ravasio R1, Giuliani G2
1Wolters Kluwer Health, Milano, Italy, 2Roche S.p.A, Milano, Italy

OBJECTIVES: To estimate the cost-effectiveness of treating interferon-naïve CHC patients with peginterferon alfa-2a (180 mcg/week) plus ribavirina (1200 mg/day) early before progression to more advanced disease. METHODS: A published Markov lifetime model was used to estimate the costs and benefits associated with early versus delayed treatment for HCV. The target population consisted of treatment-naïve HCV-1 patients with mild liver disease. The interventions were either early treatment or regular monitoring (delayed treatment) for evidence of progression to moderate or cirrhosis stage. Fibrosis progression rates came from published longitudinal cohort studies. The analysis was conducted from the perspective of the Italian NHS. Life Years Gained (LYGs) were considered, as well as Quality-Adjusted Life-Years (QALYs) and direct medical costs. LYGs and QALYs were based on the results of an international clinical trial. Benefits and costs were discounted at 3%. Sensitivity analyses were performed. RESULTS: Early treatment is expected to reduce the risk of cirrhosis at 30 years by 13.5% (23.7% early vs. 37.2% delayed), to increase mean overall survival by 0.48 years (29.77 LY early vs. 29.29 LY delayed) and to increase mean survival adjusted for quality of life by 0.75 years (14.83 QALY early vs. 14.08 QALY delayed). The expected cost (per patient) is €27,313.26 with early treatment and €22,965.37 with regular monitoring. The study calculated for early treatment versus delayed treatment the incremental cost per life year gained and per QALY gained. It was €9114.16 and €5823.92, respectively. Sensitivity analyses showed that age and social discount rate are the most influential parameters. CONCLUSION: Early treatment with peginterferon alfa-2a (40KD) plus ribavirin of CHC when this is at a mild stage is expected to reduce risk of cirrhosis, to increase life expectancy, and to be cost-effective when compared with monitoring for evidence and subsequent treatment of advanced disease.

COST-EFFECTIVENESS OF ESOMEPRAZOLE IN THE TREATMENT OF ADOLESCENT PATIENTS WITH REFLUX ESOPHAGITIS
Borrill J, Edwards SJ
Astrazeneca UK Ltd, Luton, UK

OBJECTIVES: To evaluate the cost-effectiveness of esomeprazole (40 mg once daily [od]) in adolescent patients with moderate or